Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 4, 2010, Pages 540-547

  Frymoyer, A ^a   Shugarts, S ^a   Browne, M ^a   Wu, A H B ^b   Frassetto, L ^b   Benet, L Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXYWARFARIN; 7 HYDROXYWARFARIN; COUMARIN DERIVATIVE; RIFAMPICIN; UNCLASSIFIED DRUG; WARFARIN; ANTICOAGULANT AGENT; ENZYME INHIBITOR; ORGANIC ANION TRANSPORTER;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VIVO STUDY; INTERNATIONAL NORMALIZED RATIO; LIVER CELL; LIVER METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG INTERACTION; HALF LIFE TIME; IN VITRO STUDY; METABOLIC CLEARANCE RATE; SPRAGUE DAWLEY RAT;

ANIMALS; ANTICOAGULANTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; ENZYME INHIBITORS; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; ORGANIC ANION TRANSPORTERS; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN; WARFARIN; IN VITRO TECHNIQUES;

EID: 77957019545     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.142     Document Type: Article

References (43)

1. Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A. & Hylek, E. The pharmacology and management of the vitamin K antagonists: the Seventh ACC P Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 204S-233S (2004).
2. Caldwell, M.D. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008).
3. C ooper, G.M. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027 (2008).
4. T akeuchi, F. et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433 (2009).
5. Wadelius, M. et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007).
6. Gage, B.F. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331 (2008).
7. Wadelius, M. et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113, 784-792 (2009).
8. Wu, A.H. et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9, 169-178 (2008).
9. Schelleman, H. et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin. Pharmacol. Ther. 84, 332-339 (2008).
10. Wu, C.Y. & Benet, L.Z. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22, 11-23 (2005).
11. Lau, Y.Y., Huang, Y., Frassetto, L. & Benet, L.Z. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther. 81, 194-204 (2007).
12. Zheng, H.X., Huang, Y., Frassetto, L.A. & Benet, L.Z. Elucidating rifampins inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin. Pharmacol. Ther. 85, 78-85 (2009).
13. Shugarts, S. & Benet, L.Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res. 26, 2039-2054 (2009).
14. Coumadin Tablets [package insert]. Princeton, NJ: Bristol-Meyers Squibb Company, 2007
15. Kaminsky, L.S. & Zhang, Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67-74 (1997).
16. Rifampin for Injection USP [package insert]. Bedford, OH: Bedford Laboratories, 2004
17. Baldes, C., Koenig, P., Neumann, D., Lenhof, H.P., Kohlbacher, O. & Lehr, C.M. Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1B3 (OATP1B3). Eur. J. Pharm. Biopharm. 62, 39-43 (2006).
18. Vavricka, S.R., Van Montfoort, J., Ha, H.R., Meier, P.J. & Fattinger, K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36, 164-172 (2002).
19. Israili, Z.H., Rogers, C.M. & el-Attar, H. Pharmacokinetics of antituberculosis drugs in patients. J. Clin. Pharmacol. 27, 78-83 (1987).
20. Niemi, M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8, 787-802 (2007).
21. Za, Z.M., Eloranta, J.J., Stieger, B. & Kullak-Ublick, G.A. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 9, 597-624 (2008).
22. Finch, C.K., Chrisman, C.R., Baciewicz, A.M. & Self, T.H. Rifampin and rifabutin drug interactions: an update. Arch. Intern. Med. 162, 985-992 (2002).
23. Niemi, M., Backman, J.T., Fromm, M.F., Neuvonen, P.J. & Kivist K.T. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42, 819-850 (2003).
24. Heimark, L.D., Gibaldi, M., Trager, W.F., OReilly, R.A. & Goulart, D.A. The mechanism of the warfarin-rifampin drug interaction in humans. Clin. Pharmacol. Ther. 42, 388-394 (1987).
25. Kanebratt, K.P. et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin. Pharmacol. Ther. 84, 589-594 (2008).
26. Backman, J.T., Kivist K.T., Olkkola, K.T. & Neuvonen, P.J. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 54, 53-58 (1998).
27. Bidstrup, T.B., Stilling, N., Damkier, P., Scharling, B., Thomsen, M.S. & Br̈en, K. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur. J. Clin. Pharmacol. 60, 109-114 (2004).
28. Kyrklund, C., Backman, J.T., Neuvonen, M. & Neuvonen, P.J. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol. 57, 181-187 (2004).
29. Fromm, M.F., Busse, D., Kroemer, H.K. & Eichelbaum, M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24, 796-801 (1996).
30. Ndanusa, B.U., Mustapha, A. & Abdu-Aguye, I. The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. J. Pharm. Biomed. Anal. 15, 1571-1575 (1997).
31. Washington, C., Hou, S.Y., Hughes, N.C., Campanella, C. & Berner, B. Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics. J. Clin. Pharmacol. 47, 1320-1326 (2007).
32. Lam, J.L., Okochi, H., Huang, Y. & Benet, L.Z. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab. Dispos. 34, 1336-1344 (2006).
33. Treiber, A., Schneiter, R., Hösler, S. & Stieger, B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab. Dispos. 35, 1400-1407 (2007).
34. Jiang, X. et al. Effect of St Johns wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol. 57, 592-599 (2004).
35. Jiang, X. et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol. 59, 425-432 (2005).
36. Kim, J.S., Nafziger, A.N., Gaedigk, A., Dickmann, L.J., Rettie, A.E. & Bertino, J.S. Jr. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J. Clin. Pharmacol. 41, 715-722 (2001).
37. Kong, A.N. et al. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J. Clin. Pharmacol. 35, 1008-1015 (1995).
38. Lilja, J.J., Backman, J.T. & Neuvonen, P.J. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam- probes of CYP2C9, CYP1A2, and CYP3A4. Clin. Pharmacol. Ther. 81, 833-839 (2007).
39. Mohammed Abdul, M.I. et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br. J. Pharmacol. 154, 1691-1700 (2008).
40. Soon, D. et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J. Clin. Pharmacol. 46, 1179-1187 (2006).
41. Uno, T., Sugimoto, K., Sugawara, K. & Tateishi, T. The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers. J. Clin. Pharm. Ther. 33, 67-73 (2008).
42. Loos, U., Musch, E., Jensen, J.C., Mikus, G., Schwabe, H.K. & Eichelbaum, M. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin. Wochenschr. 63, 1205-1211 (1985) .
43. Naidong, W., Ring, P.R., Midtlien, C. & Jiang, X. Development and validation of a sensitive and robust LC-tandem MS method for the analysis of warfarin enantiomers in human plasma. J. Pharm. Biomed. Anal. 25, 219-226 (2001).